MannKind Corporation (NASDAQ:MNKD) announced that Stuart A. Tross, Ph.D., has joined the company as its Chief People Officer, with responsibilities for Human Resources, Information Technology and West Coast Facilities. Dr. Tross will be integral in accelerating the company’s development into a world-class, global biopharmaceutical company centered on the value of its human capital. He will be reporting to Matthew Pfeffer, Chief Executive Officer, and will serve on MannKind’s executive leadership team.
Dr. Tross joins MannKind with several decades of leadership experience in the life sciences industry. From 2006 to 2016 he served in roles of increasing responsibility at Amgen, the last three years as Senior Vice President and Chief Human Resources Officer responsible for Human Resources and Security on a global basis. From 1998 to 2006 he served in a series of leadership roles at Bristol-Myers Squibb, the last three years as Vice President and Global Head of Human Resources for Mead Johnson Company. Stuart received a B.S. degree from Cornell University and M.S. and Ph.D. degrees in Industrial-Organization Psychology from the Georgia Institute of Technology.
“To welcome Stuart to our executive management team, with his extensive biopharmaceutical background, is both timely and opportunistic. The addition of his wide-ranging experience will be transformational at MannKind,” said Mr. Pfeffer. “Stuart’s experience will not only facilitate a quick and efficient expansion of our Afrezza launch capability, but he will be instrumental in building an organization to accommodate other strategic initiatives, such as product development and global expansion.”
Dr. Tross commented, “I am excited to join the MannKind team during this time of rapid transformation. Afrezza is an innovative product in an area of unmet patient need with significant growth potential, and there are a number of additional growth opportunities in the pipeline. I look forward to contributing to MannKind’s future.” (Original Source)
Shares of MannKind Corporation are currently falling 0.52% to $0.628, or down $0.003 in pre-market trading Wednesday. MNKD has a 1-year high of $2.24 and a 1-year low of $0.41. The stock’s 50-day moving average is $0.62 and its 200-day moving average is $0.76.
On the ratings front, J.P. Morgan analyst Cory Kasimov reiterated a Sell rating on MNKD, in a report issued on November 10. According to TipRanks.com, Kasimov has a yearly average loss of 12.3%, a 32% success rate, and is ranked #4256 out of 4351 analysts.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.